AI-CVD vs LINQ II Insertable Cardiac Monitor
AI Verdict
Choose AI-CVD if…
Choose AI-CVD if your primary objective is opportunistic screening for cardiovascular and multisystem disease risks using existing CT scans, without requiring additional imaging or patient burden. This platform is ideal for leveraging previously acquired chest or abdominal CT data to identify hidden health risks through automated measurements like Coronary Artery Calcium (CAC) scoring and cardiac chamber volumetry.
View AI-CVD →Choose LINQ II Insertable Cardiac Monitor if…
Choose the LINQ II Insertable Cardiac Monitor if you need long-term, continuous heart rhythm monitoring for the diagnosis of infrequent or paroxysmal arrhythmias that are difficult to capture with shorter-term methods. This device is best suited for patients experiencing symptoms such as unexplained syncope, cryptogenic stroke, or palpitations, where prolonged monitoring (up to 4.5 years) with AI-powered accuracy and remote management is crucial to detect elusive cardiac events.
View LINQ II Insertable Cardiac Monitor →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AI-CVD | LINQ II Insertable Cardiac Monitor |
|---|---|---|
| Deployment | Unknown | Subcutaneous implant with remote monitoring via mobile app or home communicator. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AI-CVDAI-CVD integrates seamlessly into existing radiology workflows by utilizing pre-existing CT scans, eliminating the need for additional procedures, radiation, or workflow disruption. In contrast, LINQ II requires an initial invasive surgical procedure for implantation, which presents a higher barrier to usability for the patient.
Clinical Value
AI-CVDAI-CVD offers broad clinical value through opportunistic screening of existing CT scans, enabling early detection of multiple cardiovascular and multisystem diseases, such as coronary heart disease, heart failure, atrial fibrillation, stroke, osteoporosis, and liver steatosis. While LINQ II provides critical, highly accurate long-term arrhythmia diagnosis, AI-CVD's ability to leverage existing data for proactive health management across various conditions gives it a slight edge in population-level impact.
Pricing & Value
AI-CVDAI-CVD provides significant value by utilizing existing CT scan data to generate new, critical health insights without requiring additional imaging procedures or associated costs. This approach maximizes the return on existing healthcare investments. LINQ II, while valuable, involves the cost of an implantable device and a surgical procedure, with pricing typically negotiated and not publicly disclosed.
Enterprise Readiness
LINQ II Insertable Cardiac MonitorMedtronic is a globally established medical device company with a long history and a proven track record, having served over 1 million patients with ICMs worldwide. Its explicit HIPAA compliance and extensive infrastructure demonstrate a higher level of enterprise readiness compared to HeartLung Corporation, which provides less public detail on these critical aspects.
Innovation
AI-CVDAI-CVD's innovative strength lies in its paradigm-shifting approach of performing opportunistic screening for multiple cardiovascular and multisystem diseases using existing CT scans. This leverages previously untapped data to provide early detection without additional patient burden, representing a more disruptive innovation than the iterative advancements seen in LINQ II.
Support & Docs
LINQ II Insertable Cardiac MonitorAs a large, established medical device manufacturer, Medtronic offers extensive and well-documented support resources for its products, including the LINQ II, for both clinicians and patients, with dedicated technical and patient service lines. HeartLung Corporation, being a smaller entity, does not publicly provide the same level of detailed support and documentation.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AI-CVD | LINQ II Insertable Cardiac Monitor |
|---|---|---|
| Name | AI-CVD | LINQ II Insertable Cardiac Monitor |
| Company | HeartLung Corporation | Medtronic |
| Description | FDA-cleared, AI-powered quantitative imaging platform that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks. | Advanced, AI-powered insertable cardiac monitor providing long-term, continuous heart rhythm monitoring with remote programming and enhanced accuracy for diagnosing arrhythmias. |
| Categories | Cardiology AI | Cardiology AI, Clinical Decision Support & Reference |
| Specialties | Cardiology, Pulmonology, Radiology | Cardiology |
| Key Features | Automated CT-derived anatomical and density-based measurements, Opportunistic screening from existing chest and abdominal CT scans, No additional imaging, radiation, contrast, or workflow disruption, Coronary Artery Calcium (CAC) scoring, Aortic wall, aortic valve, and mitral valve calcium analysis, Cardiac chamber volumetry (Left Atrium, Left Ventricle, Right Atrium, Right Ventricle), Epicardial fat volumetry, Aorta and pulmonary artery sizing | AccuRhythmu2122 AI algorithms for enhanced accuracy, Remote programming capability, Up to 4.5 years of continuous monitoring, MRI compatibility (1.5 and 3.0T), MyCareLink Heartu2122 mobile app for data transmission, MyCareLink Relayu2122 home communicator option, Innovative PVC detection algorithm, Pediatric indication (ages 2+) |
Videos
Demos, reviews, and walkthroughs featuring AI-CVD and LINQ II Insertable Cardiac Monitor.